AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Bronstein, Gewirtz & Grossman, LLC Class Action Update - UXIN, SGYP & MHLD

March 29, 2019

NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Uxin Limited (NASDAQ: UXIN) Class Period: shares purchased pursuant and/or traceable to the Company’s June 27, 2018, initial public offering (“IPO”) For more info: www.bgandg.com/uxin

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information in its filings with the U.S. Securities and Exchange Commission in connection with its IPO.

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP ) Class Period: September 5, 2017 - October 25, 2018 Lead Plaintiff Deadline: April 12, 2019 For more info: www.bgandg.com/sgyp

On October 25, 2018, the Company shocked its investors and the market by revealing that: (i) TRULANCE had substantially disappointed and that its launch and integration into the marketplace was not as successful as represented; (ii) as a result, the Company faced substantial risk that it would not be able to satisfy the minimum revenue, market capitalization and liquidity requirements in the CRG Loan; (iii) Synergy’s efforts to renegotiate the terms of the CRG Loan had proven unsuccessful; and (iv) the strategic review process had failed to yield a “white knight” or financing alternative and was unlikely to do so prior to default on the Company’s covenants to CRG. Following this news, Synergy’s stock price fell $0.97 per share, or 69.3%, to close at $0.43 per share on October 26, 2018.

Maiden Holdings, Ltd. (NASDAQ: MHLD) Class Period: March 4, 2014 - November 9, 2018 Deadline: April 12, 2019 For more info: www.bgandg.com/mhld

The Complaint alleges that throughout the Class Period, Defendants failed to disclose material information. Specifically, the complaint alleges that Defendants misrepresented the quality and nature of Maiden’s underwriting and risk management policies and practices and the risks of its reinsurance portfolio.

Contact:Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com